December 15, 2020 - December 15, 2021



Multiple myeloma is the second-most common blood cancer in the United States, with an estimated 32,110 new cases and 12,960 related deaths anticipated in 2019. Despite substantial progress in treatment, prognosis and survival remain suboptimal in this disease, which is marked by substantial morbidity and reduced quality of life. Multiple myeloma and its treatment affect nearly every body system. In this podcast, Dr. Beth Faiman will summarize the latest developments in myeloma treatment, including a brief update on Bi-specific T cell engagers (BiTE ) and CAR T-cell therapy, in addition to a review of other recently approved therapies.

Target Audience
This activity has been designed to meet the educational needs of physicians, nurse practitioners (NPs), physician assistants (PAs) and oncology nurses who manage patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Summarize the latest developments in myeloma treatment that have changed management options for patients with myeloma
  • Devise treatment plans for multiple myeloma with consideration for age/frailty and other patient and disease characteristics

Activity Launch Date - 12/23/2020
Expiration Date - 12/23/2021

Disclosure of Commercial Support
This activity is supported by an independent medical education grant Sanofi Genzyme.

Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.

Copyright Information
Copyright © 2020 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.


Time Description
3 min


21 min

PODCAST: Understanding the Rapidly Evolving Science and Best Practices in Multiple Myeloma

3 min


9 min

Final Evaluation

Faculty & Disclosures

Faculty & Disclosures

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN, FAAN
Nurse Practitioner and Nurse Scientist
Cleveland Clinic
Department of Hematology and Medical Oncology
Cleveland, OH

Faculty Bio

Beth Faiman PhD, MSN, APRN-BC, AOCN received a bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014.

Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio. She is adjunct faculty at Ursuline College, Case Western Reserve University and Kent State University. She received the 2012 Excellence in Medical Oncology and 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University and was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016.

Dr. Faiman is an active author, presenter, and educator on the topic of multiple myeloma, chronic lymphocytic leukemia, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. She is currently Editor-in-Chief of the Oncology Nurse APN/PA and on the editorial board of ASH Clinical News among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management.

Faculty Disclosure Statement
Beth Faiman has served as a consultant for Bristol Myers Squibb, Sanofi, and GSK.

Planning Committee & Non-faculty Contributors
Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclose no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months.

Learner Assurance Statement
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

CE Information

Launch Date/Expiration Date
This activity was launched on December 23, 2020 and will expire on December 23, 2021.

Accreditation Statement
Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Horizon CME designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How To Claim Credit

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity pre-test and post-test
  • Complete Final Evaluation

Any questions? Please check out our FAQs section or feel free to contact us.